NO955189L - En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet - Google Patents

En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet

Info

Publication number
NO955189L
NO955189L NO955189A NO955189A NO955189L NO 955189 L NO955189 L NO 955189L NO 955189 A NO955189 A NO 955189A NO 955189 A NO955189 A NO 955189A NO 955189 L NO955189 L NO 955189L
Authority
NO
Norway
Prior art keywords
growth factor
keratinocyte growth
disclosed
kgf
abbreviated
Prior art date
Application number
NO955189A
Other languages
English (en)
Other versions
NO955189D0 (no
Inventor
Denis Gospodarowicz
Frank Masiarz
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO955189L publication Critical patent/NO955189L/no
Publication of NO955189D0 publication Critical patent/NO955189D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Et keratinocyt vekstfaktorfragment, KGFdesi_23 som består av en del av en aminosyresekvens fra moden, full-lengde kratinocytvekstfaktor, KGF163. Delen har minst en 2-ganger økning i mitogen aktivitet sammen- lignet med en moden, rekombinant keratinocyt vekst- faktor, rKGF, men mangler en sekvens som omfatter de første 23 amlnosyreresldiene, C-N-D-M-T-P-E-Q-M-A-T-N- V-N-C-S-S-P-E-R-H-T-R- av KGF163 N-terminale ende, er beskrevet. Et DNA molekyl kodende for KGF(jesl-23' en ekspresjonsvektor og en transformert vert inneholdende DNA molekylet og en fremgangsmåte for produsering av KGFdesl-23 vec* dyrking av den transformerte verten er også beskrevet. Videre er et konjugat av KGFdesl_23 og et toksinmolekyl, anvendelse derav for behandling av hyperprollferatlv sykdom l epidermis, en terapeutlks sammensetning Inneholdende KGFdesl_23, en farmasøytisk akseptabel bærer og anvendelse derav for leging av sår, også beskrevet.
NO955189A 1993-06-29 1995-12-20 En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet NO955189D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8642793A 1993-06-29 1993-06-29
PCT/US1994/004694 WO1995001434A1 (en) 1993-06-29 1994-04-28 A truncated keratinocyte growth factor (kgf) having increased biological activity

Publications (2)

Publication Number Publication Date
NO955189L true NO955189L (no) 1995-12-20
NO955189D0 NO955189D0 (no) 1995-12-20

Family

ID=22198501

Family Applications (1)

Application Number Title Priority Date Filing Date
NO955189A NO955189D0 (no) 1993-06-29 1995-12-20 En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet

Country Status (25)

Country Link
US (7) US5677278A (no)
EP (2) EP1493812A3 (no)
JP (4) JP3570516B2 (no)
KR (1) KR960703433A (no)
CN (1) CN1129955A (no)
AT (1) ATE278777T1 (no)
AU (1) AU681405B2 (no)
BG (1) BG100236A (no)
BR (1) BR9407035A (no)
CA (1) CA2166278A1 (no)
CZ (1) CZ343795A3 (no)
DE (2) DE69434053T2 (no)
DK (1) DK0706563T3 (no)
ES (1) ES2227527T3 (no)
FI (1) FI956203A (no)
FR (1) FR06C0004I2 (no)
HU (1) HUT73453A (no)
LU (1) LU91215I2 (no)
NL (1) NL300217I2 (no)
NO (1) NO955189D0 (no)
NZ (1) NZ266622A (no)
PL (1) PL312257A1 (no)
PT (1) PT706563E (no)
SK (1) SK153295A3 (no)
WO (1) WO1995001434A1 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555205B1 (en) * 1989-01-31 2000-11-29 RUBIN, Jeffrey S Dna encoding a growth factor specific for epithelial cells
US7026291B1 (en) 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
US5814605A (en) * 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
PT706563E (pt) 1993-06-29 2005-01-31 Chiron Corp Factor de crescimento de queratinocitos (kgf) truncado, com actividade biologica aumentada
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
ES2197926T3 (es) * 1994-10-13 2004-01-16 Amgen Inc. Metodo para purificar factores de crecimiento de queratinocitos.
AU745815B2 (en) * 1994-10-13 2002-04-11 Biovitrum Ab (Publ) Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
CA2202075C (en) * 1994-10-13 2003-12-09 Charles F. Morris Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
ES2293137T3 (es) * 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
JP2001506975A (ja) * 1996-10-15 2001-05-29 アムジェン インコーポレイテッド ケラチノサイト増殖因子―２産物
EP1003770A4 (en) * 1997-06-19 2002-10-30 Inst Genetics Llc SECRETIED POLYPEPTIDES AND THESE ENCODING POLYNUCLEOTIDES
US20080233086A1 (en) * 1997-09-05 2008-09-25 Canbiocin Inc. Expression Vectors for Treating Bacterial Infections
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
CA2316015A1 (en) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
CA2320515A1 (en) * 1998-02-13 1999-08-19 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
DE19934510B4 (de) * 1999-07-22 2009-04-16 Vermicon Ag Verfahren zum Nachweis von Mikroorganismen
US6485937B1 (en) 1999-10-15 2002-11-26 The Rockefeller University System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
DE10024334B4 (de) * 2000-05-17 2006-06-01 Medigene Ag Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat
US6812221B2 (en) 2000-11-21 2004-11-02 The Texas A&M University System FGF-affinity chromatography
WO2002077155A2 (en) * 2001-01-08 2002-10-03 Human Genome Sciences, Inc. Keratinocyte growth factor-2
KR100899970B1 (ko) 2001-02-19 2009-05-28 메르크 파텐트 게엠베하 Ｔ-세포 에피토프의 동정 방법 및 감소된 면역원성을 갖는분자의 제조를 위한 용도
US7265089B2 (en) 2001-08-21 2007-09-04 Chiron Corporation KGF polypeptide compositions
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
SI1827483T1 (sl) * 2004-12-15 2014-11-28 Swedish Orphan Biovitrum Ab (Publ) Terapevtske formulacije keratinocitnega rastnega faktorja
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
CA2630220C (en) * 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
WO2008005533A2 (en) * 2006-07-06 2008-01-10 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
US9132202B2 (en) 2009-07-17 2015-09-15 Aaron T. Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
JP2016535770A (ja) 2013-11-01 2016-11-17 スフェリウム バイオメッド エス．エル． 治療用及び美容用物質を経皮送達するための封入体
AU2022336409A1 (en) 2021-08-30 2024-02-15 Unichem Laboratories Limited Protein compositions for the treatment of inflammatory diseases
KR20230070596A (ko) * 2021-11-15 2023-05-23 (주)피앤피바이오팜 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555205B1 (en) * 1989-01-31 2000-11-29 RUBIN, Jeffrey S Dna encoding a growth factor specific for epithelial cells
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5814605A (en) 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
PT706563E (pt) * 1993-06-29 2005-01-31 Chiron Corp Factor de crescimento de queratinocitos (kgf) truncado, com actividade biologica aumentada
CA2202390C (en) 1994-10-13 2005-05-17 Bao-Lu Chen Keratinocyte growth factor analogs
CA2202075C (en) 1994-10-13 2003-12-09 Charles F. Morris Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using

Also Published As

Publication number Publication date
NZ266622A (en) 1997-10-24
US5843883A (en) 1998-12-01
CN1129955A (zh) 1996-08-28
JP3570516B2 (ja) 2004-09-29
WO1995001434A1 (en) 1995-01-12
JP2006075173A (ja) 2006-03-23
US6677301B1 (en) 2004-01-13
US5863767A (en) 1999-01-26
FR06C0004I2 (fr) 2006-12-29
JP2009062396A (ja) 2009-03-26
DK0706563T3 (da) 2005-01-31
ATE278777T1 (de) 2004-10-15
BG100236A (en) 1996-07-31
KR960703433A (ko) 1996-08-17
DE122006000005I2 (de) 2006-11-23
DE69434053D1 (de) 2005-01-20
EP1493812A2 (en) 2005-01-05
FI956203A0 (fi) 1995-12-22
JP4662569B2 (ja) 2011-03-30
BR9407035A (pt) 1996-03-12
NL300217I2 (nl) 2006-05-01
JP2004166709A (ja) 2004-06-17
CZ343795A3 (en) 1996-07-17
US20090093400A1 (en) 2009-04-09
ES2227527T3 (es) 2005-04-01
FI956203A (fi) 1996-02-07
JPH09500267A (ja) 1997-01-14
US5677278A (en) 1997-10-14
EP1493812A3 (en) 2006-02-08
EP0706563B1 (en) 2004-10-06
US5773586A (en) 1998-06-30
HUT73453A (en) 1996-08-28
PL312257A1 (en) 1996-04-01
NO955189D0 (no) 1995-12-20
CA2166278A1 (en) 1995-01-12
AU681405B2 (en) 1997-08-28
PT706563E (pt) 2005-01-31
EP0706563A1 (en) 1996-04-17
FR06C0004I1 (no) 2006-03-10
DE122006000005I1 (de) 2006-08-10
AU6820894A (en) 1995-01-24
NL300217I1 (nl) 2006-04-03
US6074848A (en) 2000-06-13
LU91215I2 (en) 2006-03-27
DE69434053T2 (de) 2006-02-23
SK153295A3 (en) 1996-11-06
HU9503857D0 (en) 1996-02-28

Similar Documents

Publication Publication Date Title
NO955189L (no) En forkortet keratinocyt vekstfaktor (KGF) med ökende biologisk aktivitet
CA1223198A (en) Repair of tissue in animals
Thomas et al. Fibroblast growth factors: broad spectrum mitogens with potent angiogenic activity
US4785079A (en) Isolation of fibroblast growth factor
EP0492614B1 (en) Epitheliocyte growth accelerator
JPH02504279A (ja) インスリン様成長因子１（ｉｇｆ‐１）または因子２（ｉｇｆ‐２）の類縁ペプチド
IL141494A0 (en) Stable hypoxia inducible factor-1 alpha and method of use
KR970700438A (ko) 마크로파지 염증성 단백질-3,-4 및 -1감마(MACROPHAGE INFLAMMATORY PROTEINS -3,-4 AND -1sg(g))
CA2223433A1 (en) Ob protein compositions and methods
BR9408006A (pt) Molécula de ácido nucléico isolada e purificada vetor e vetor de express o adaptados para transformaçao de hospedeiro hospedeiro transformado proteina receptora "transferrin" recombinante ou fragmento ou análogo da mesma proteina Tbpl purificada e isolada proteina Tbp2 purificada e isolada peptídeo composiç o imunogênica vetor ativo para fornecimento de proteina receptora "transferrin" vetor de plasmideo linhagem de haemophilus processo para produzir proteina Tbp2 ou Tbpl purificada e isolada
FR2644066B1 (fr) Compositions stabilisees comprenant des fgfs, leur procede d'obtention et leurs applications therapeutiques, chirurgicales et cosmetologiques
Laato et al. Effect of epidermal growth factor (EGF) on experimental granulation tissue
US4902782A (en) Isolation of fibroblast growth factor
EP0410671B1 (en) Acylated epidermal growth factor
US5358707A (en) Oxidized variants of GM-CSF
DE69329337D1 (de) Antibiotisches cryptdinpeptid und anwendungsmethoden
EP0526883B1 (en) Chondromodulin-II protein
EP0557319B1 (en) Therapeutic use of fibroblast growth factor
JP3195793B2 (ja) 成長因子の組成、調製および使用
AU632890B2 (en) Fibroblast growth factor for use in the prevention and treatment of viral infections
DE69433221D1 (de) Neues Chondrozytprotein
EP0494664A1 (en) Human bFGF derivatives, their analogs and process for their production
US5883071A (en) Mammalian growth factor
RU95122751A (ru) Укороченный кератиноцитарный фактор роста с повышенной биологической активностью
Thomas et al. Primary structure and mitogenic and angiogenic activities of brain-derived acidic fibroblast growth factor